Gynecologic Cancer
Latest News
ASCO details how to manage ongoing cancer drug shortage
“This guidance document aims to support clinicians, as they navigate the complexities of treatment planning amid the drug shortage.”
Conference Coverage
Later-line tisotumab vedotin shows survival benefit in metastatic cervical CA
Results are similar to cemiplimab, but unlike TV, cemiplimab is not yet approved for the indication.
Latest News
Induction chemotherapy in first line improves survival for locally advanced cervical cancer
With similar results reported for pembrolizumab, a question has arisen about how to incorporate induction chemotherapy and pembrolizumab into a...
Conference Coverage
Chemo-immunotherapy good, adding a PARP inhibitor better in endometrial cancer?
Dr. Tan noted, the AtTEnd data "continue to validate practice-changing therapy for dMMR endometrial cancer patients."
Conference Coverage
Does first-line pembrolizumab add-on improve PFS in high-risk cervical cancer?
An FDA decision is expected in January on pembrolizumab with concurrent chemoradiotherapy for the first-line treatment of locally advanced...
Feature
What is the future for multicancer early-detection tests?
Liquid biopsies based on genomic biomarkers could make MCED a reality, especially for cancers for which there is no standard screening process.
Conference Coverage
Cervical cancer: Vaginal dilation linked to less stenosis after treatment
Sexual intercourse and dilator use may reduce risk of vaginal stenosis following treatment for cervical cancer.
From the Journals
Cancer incidence has increased in patients under age 50
“Prevention and early detection measures are urgently required, along with identifying optimal treatment strategies for early-onset cancers, which...
Commentary
Two landmark papers change treatment paradigm for advanced endometrial cancer
The outcomes we have now are remarkably positive for patients and have absolutely changed the standard of care in the management of recurrent or...
From the Journals
Surgery approach may improve survival in advanced ovarian cancer
From the Journals
Delaying palliative chemo may improve QoL without affecting survival for asymptomatic patients
For asymptomatic patients, delaying the start of systemic therapy should be discussed with the patient.